Teva Pharmaceutical Industries Limited

Bio-lab, Inc.

Qbi Enterprises Ltd.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Siolab Ltd.

Nasvax Ltd.

Jean Hildesheim

Ben-Zion Dolitzky

Judith Aronhime

Shoshana Ben-Valid

Sergey Finogueev

Serguei Finogueev

Jean-Christophe Truffert

Tirtsa Kleinman

Shlomit Wizel

Sharon Avkin-Nachum

Ilan Kor

Myriam Lefoix

Alisa Berlin

Aaron Garzon

Hagit Eisen-Nevo

Sergei Fine

Elimelech Rochlin

Ilan Kor-Sade

Eran Luvchick

Reuven Izsak

IIan Kor

Gerald Mathis

Disclosed herein are double-stranded RNA nucleic acid molecules, which include at least one pyrazolotriazine nucleotide analog and have been modified to exhibit one of the following, increased on-target activity, increased target specificity, enhanced nuclease stability, reduced off target activity and/or reduced immunogenicity when compared to an unmodified or similarly modified dsRNA; pharmaceutical compositions comprising such molecules and methods of use thereof in therapy.

Therapeutic oligonucleotides comprising pyrazolotriazine nucleotide analogues

The present invention relates to pyrazolotriazolyl nucleoside analogs, such as 

Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them

Provided herein are sphingolipid-polyalkylamine phosphoramidites, methods of generating sphingolipid-polyalkylamine-oligonucleotide compounds, pharmaceutical compositions comprising such compounds, and to methods of use thereof in treating cancer.

Sphingolipid-polyalkylamine-oligonucleotide compounds

The present disclosure provides processes for the preparation of lipid conjugated cyclic carbonate derivatives. More specifically, the present disclosure is based on the finding that reacting lipids, such as, ceramides, with N,N'-disuccinimidyl derivative, resulted in the formation of, isolatable, substituted cyclic [1,3]-dioxan-2-one and [1,3]-dioxan-2-thione compounds. These isolatable cyclic substituted compounds and derivatives thereof may be used for various applications, such as in vaccination.

Lipid conjugated cyclic carbonate derivatives, their synthesis, and uses

Novel cyclic and acyclic oxazaphospholanes are described, as well as their use in the synthesis of sphingomyelin and sphingomyelin analogous. The production of synthetic sphingomyelins is also described. 2S, 3R stereoisomers of oxazaphospholanes and sphingomyelins, and synthetic methods for their preparation are described.

Sphingomyelin, intermediates thereof and methods for preparation of same

This invention relates to an improved process of preparing carvedilol, as well as a new crystalline hydrate and solvate and forms of carvedilol, processes for the manufacture thereof, and pharmaceutical compositions thereof.

Carvedilol

Provided is a novel crystal form of pioglitazone hydrochloride and a method for making it. Also provided is a method for making a known crystal form of pioglitazone hydrochloride.

Pioglitazone hydrochloride

The invention encompasses aripiprazole crystalline forms, methods of preparing the same, and pharmaceutical compositions having aripiprazole crystalline forms.

Methods of preparing aripiprazole crystalline forms

The invention encompasses synthesizing 7-(4-bromobutoxy)-3,4-dihydrocarbostyril by mixing 7-hydroxy-tetrahydroquinolinone, dibromobutane, and at least one base to form a reaction mixture; heating the reaction mixture; cooling the reaction mixture; and isolating the 7-(4-bromobutoxy)-3,4-dihydrocarbostyril from the reaction mixture. The invention also encompasses using phase transfer catalysts during the reaction.

Method of making 7-(4-bromobutoxy)-3,4-dihydrocarbostyril

The invention relates to a method of making optically and chemically pure levetiracetam and to the levetiracetam produced by such process.

Growing community of inventors

Mazkeret Batya, Israel

Jean Hildesheim